Carcinogenesis, Vol. 21, No. 6, 1227-1232,
June 2000
© 2000 Oxford University Press
Carcinogenesis |
Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase
Laboratory of Drug Metabolism, Division of Pharmacobio-dynamics, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido 060-0812,
1 Division of Genetics and Mutagenesis, National Institute of Health Sciences, Setagaya-ku Tokyo 158-8501 and
2 Central Research Laboratories, Tsumura & Co., Inashiki-gun, Ibaraki 300-1192, Japan
A Salmonella typhimurium tester strain YG7108 2E1/OR co-expressing human CYP2E1 together with human NADPH-cytochrome P450 reductase (OR) was established. The mutagen-activating capacity of human CYP2E1 for N-alkylnitrosamines was compared with that of CYP2A6 using the YG7108 2E1/OR and the YG7108 2A6/OR strains of Salmonella. Salmonella YG7108 2A6/OR is a derivative of YG7108 co-expressing CYP2A6 together with OR. Eight N-alkylnitrosamines, including N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA), N-nitrosodipropylamine (NDPA), N-nitrosodibutylamine (NDBA), N-nitrosomethylphenylamine (NMPhA), N-nitrosopyrrolidine (NPYR), N-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) were examined. CYP2E1 expressed in the YG7108 2E1/OR cells showed mutagen-activating capacity, as indicated by induced revertants/min/pmol cytochrome P450, for NDMA, NDEA, NDPA, NDBA, NPYR and NNK, but not NMPhA and NNN. CYP2A6 activated NDMA, NDEA, NDPA, NDBA, NMPhA, NPYR, NNN and NNK. The ratio of the mutagen-activating capacity seen with CYP2A6 to that seen with CYP2E1 was calculated for each N-alkylnitrosamine. In the case of NDMA, NPYR and NDEA, the ratio was under 1.0, while the ratio was over 1.0 with NDPA, NDBA, NNK, NMPhA and NNN. We conclude that human CYP2E1 is mainly responsible for the metabolic activation of N-nitrosamines with a relatively short alkyl chain(s), whereas CYP2A6 was predominantly responsible for the metabolic activation of N-alkylnitrosamines possessing a relatively bulky alkyl chain(s).
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. S. Kang, H. Wanibuchi, K. Morimura, F. J. Gonzalez, and S. Fukushima Role of CYP2E1 in Diethylnitrosamine-Induced Hepatocarcinogenesis In vivo Cancer Res., December 1, 2007; 67(23): 11141 - 11146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Lee, J. Yue, and R. F. Tyndale In Vivo and in Vitro Characterization of Chlorzoxazone Metabolism and Hepatic CYP2E1 Levels in African Green Monkeys: Induction by Chronic Nicotine Treatment Drug Metab. Dispos., September 1, 2006; 34(9): 1508 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Miyazaki, H. Yamazaki, H. Takeuchi, K. Saoo, M. Yokohira, K.-i. Masumura, T. Nohmi, Y. Funae, K. Imaida, and T. Kamataki Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas Carcinogenesis, November 1, 2005; 26(11): 1947 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Duarte, B. B. Palma, A. Laires, J. S. Oliveira, J. Rueff, and M. Kranendonk Escherichia coli BTC, a human cytochrome P450 competent tester strain with a high sensitivity towards alkylating agents: involvement of alkyltransferases in the repair of DNA damage induced by aromatic amines Mutagenesis, May 1, 2005; 20(3): 199 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hakura, H. Shimada, M. Nakajima, H. Sui, S. Kitamoto, S. Suzuki, and T. Satoh Salmonella/human S9 mutagenicity test: a collaborative study with 58 compounds Mutagenesis, May 1, 2005; 20(3): 217 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W J Lee, W Lijinsky, E F Heineman, R S Markin, D D Weisenburger, and M H Ward Agricultural pesticide use and adenocarcinomas of the stomach and oesophagus Occup. Environ. Med., September 1, 2004; 61(9): 743 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takeuchi, K. Saoo, M. Yokohira, M. Ikeda, H. Maeta, M. Miyazaki, H. Yamazaki, T. Kamataki, and K. Imaida Pretreatment with 8-Methoxypsoralen, a Potent Human CYP2A6 Inhibitor, Strongly Inhibits Lung Tumorigenesis Induced by 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone in Female A/J Mice Cancer Res., November 15, 2003; 63(22): 7581 - 7583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. J. Smith, J. R. Bend, L. L. Bedard, K. R. Reid, D. Petsikas, and T. E. Massey BIOTRANSFORMATION OF 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE (NNK) IN PERIPHERAL HUMAN LUNG MICROSOMES Drug Metab. Dispos., September 1, 2003; 31(9): 1134 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Stellman, T. Takezaki, L. Wang, Y. Chen, M. L. Citron, M. V. Djordjevic, S. Harlap, J. E. Muscat, A. I. Neugut, E. L. Wynder, et al. Smoking and Lung Cancer Risk in American and Japanese Men: An International Case-Control Study Cancer Epidemiol. Biomarkers Prev., November 1, 2001; 10(11): 1193 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Fujita and T. Kamataki Screening Of Organosulfur Compounds as Inhibitors of Human CYP2A6 Drug Metab. Dispos., July 1, 2001; 29(7): 983 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Okabe, S. Satoh, T. Kato, O. Kitahara, R. Yanagawa, Y. Yamaoka, T. Tsunoda, Y. Furukawa, and Y. Nakamura Genome-wide Analysis of Gene Expression in Human Hepatocellular Carcinomas Using cDNA Microarray: Identification of Genes Involved in Viral Carcinogenesis and Tumor Progression Cancer Res., March 1, 2001; 61(5): 2129 - 2137. [Abstract] [Full Text]
|
|